'Hard,' 'soft' and 'surrogate' endpoints in diabetes

Journal of Epidemiology and Community Health

Volumn 67, Issue 4, 2013, Pages 295-297

  Yudkin, John S ^a   Eggleston, Emma M ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN;

COST-BENEFIT ANALYSIS; DIABETES; DISEASE CONTROL; DISEASE PREVALENCE; EPIDEMIOLOGY; HEALTH RISK; PUBLIC HEALTH;

ARTICLE; BLOOD; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS;

EID: 84875050072     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech-2012-201361     Document Type: Article

References (25)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet 1998;352:837-5
2. Yudkin JS, Lipska K, Montori V. The idolatry of the surrogate. BMJ 2011;343:d799
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-9
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-
5. Borch-Johnsen K, Colagiuri S, Balkau B, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glucose. Diabetologia 2004;47:1396-40
6. East of England Public Health Observatory. Chronic disease prevalence by age and sex for 2008 in England by IMD 2007 quintile. http://www.erpho.org.uk/Download/Public/20575/1/P3043%20Chronic %20disease%20prevalence%20by%20age%20and %20sex%20for%202008%20in%20England%20by %20IM (accessed 9 Sep 2012).
7. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-5
8. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-7
9. Duckworth W, Abraira C, Moritz T, et al., for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-3
10. Lehman R, Yudkin JS, Krumholz H. Licensing drugs for diabetes. BMJ 2010;341:c480
11. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry. Diabetes mellitus-evaluating cardiovascular risk in antidiabetic therapies to treat type 2 diabetes. DHHS http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM07162 pdf (accessed 3 November 2012).
12. National Institute for Health and Clinical Excellence. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes. NICE technology appraisal guidance 24 February 201 http://www. nice.org.uk/nicemedia/live/13670/58205/5820 pdf(accessed 9 Sep 2012).
13. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35): prospective observational study. BMJ 2000;321:405-1
14. Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010;53:2079-8
15. Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012;172:761-9
16. ACCORD Study Group and ACCORD Eye Study Group. Effect of medical therapies on retinopathy progression in type 2 diabetes (correction in: N Engl J Med 2011;364:190). N Engl J Med 2010;363:233-4
17. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343:d416
18. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-8
19. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:595-60
20. Chow EA, Foster H, Gonzalez V, et al. The disparate impact of diabetes on racial/ethnic minority populations. Clinical Diabetes 2012;30:130-
21. Whiting DR, Guariguata L, Weil C, et al. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 203 Diabetes Res Clin Pract 2011;94:311-2
22. The writing group for the SEARCH for Diabetes in Youth study group. Incidence of diabetes in youth in the US. JAMA 2007;297:2716-2
23. Chan J, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-4
24. Stiggelbout AM, Van der Weijden T, De Wit MP, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ 2012; 344:e25
25. Timbie JW, Hayward RA, Vijan S. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med 2010;170:1037-4